Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sonoma Pharmaceuticals (SNOA) Retained Earnings (2016 - 2025)

Sonoma Pharmaceuticals has reported Retained Earnings over the past 15 years, most recently at -$200.4 million for Q4 2025.

  • For Q4 2025, Retained Earnings fell 1.71% year-over-year to -$200.4 million; the TTM value through Dec 2025 reached -$200.4 million, down 1.71%, while the annual FY2025 figure was -$197.8 million, 1.78% down from the prior year.
  • Retained Earnings for Q4 2025 was -$200.4 million at Sonoma Pharmaceuticals, down from -$3.4 million in the prior quarter.
  • Over five years, Retained Earnings peaked at -$2.8 million in Q4 2023 and troughed at -$200.4 million in Q4 2025.
  • A 5-year average of -$125.2 million and a median of -$180.9 million in 2021 define the central range for Retained Earnings.
  • Biggest five-year swings in Retained Earnings: soared 98.32% in 2023 and later plummeted 6879.45% in 2024.
  • Year by year, Retained Earnings stood at -$181.4 million in 2021, then skyrocketed by 97.7% to -$4.2 million in 2022, then surged by 32.4% to -$2.8 million in 2023, then plummeted by 6879.45% to -$197.0 million in 2024, then fell by 1.71% to -$200.4 million in 2025.
  • Business Quant data shows Retained Earnings for SNOA at -$200.4 million in Q4 2025, -$3.4 million in Q3 2025, and -$199.0 million in Q2 2025.